Search results

Articles (7)

Journals (0)

1-7 of 7 results for FDA-1639

Sort by:

Relevance

Select all

Sort by:

Relevance

Retricted access

Research article

First published 1994-1

Completeness of Adverse Drug Experience Reporting to the FDA: II. A Comparison of Manufacturer and Direct Reports on New Molecular Entities

Annie L. Britt, Deanne E. Knapp

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1986-4

Experience with the who Adverse Reaction Terminology at Searle

Irvin Strathman

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1988-1

A Pilot Study of Electronic Submission of Periodic Reports to the FDA: Flexible Diskette Submission-Glaxo Program Development

Joel H. Dobbs

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 1989-4

Electronic Submission of Periodic Reports

Charles Anello

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 1989-4

Database Management and Reporting Systems — Foreign-Based Companies: The Glaxo Approach

John C. C. Talbot

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1993-10

The Evaluation of Postmarketing Adverse Drug Experience Reports at FDA: Part I

Joyce M. Johnson, L. Ann Tanner, David Barash

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1991-10

Completeness of Adverse Drug Experience Reporting by Manufacturers to the FDA

Annie L. Britt, Deanne E. Knapp, Charles Anello [...]

Therapeutic Innovation & Regulatory Science